Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) according to 2018 international diagnostic guidelines
• People who have measurable signs of the disease, such as a high white blood cell count, enlarged lymph nodes of a certain size, or significant bone marrow involvement
• People who have never received systemic (whole-body) treatment for CLL or SLL before
• People whose disease currently meets the 2018 guidelines indicating that treatment is needed
• People aged 18 or older
• People who are reasonably well and able to carry out daily activities (as assessed by a standard medical scale)
• People whose organs and bone marrow are functioning well enough, as defined by the study's requirements
• People who are able to swallow and take oral (by mouth) medications
• People who are willing and able to understand and sign a written consent form

Who may not be able to join:

• People whose CLL has transformed into a more aggressive type of lymphoma (Richter's transformation), or whose cancer has spread to the brain or spinal cord
• People with a history of bleeding disorders
• People who have had a stroke or bleeding in the brain within the 6 months before starting the study
• People with serious heart conditions, such as an uncontrolled irregular heartbeat, severe heart failure, or poor heart pumping function measured within the past 12 months
• People with a history of another cancer where life expectancy is less than 2 years
• People currently taking part in another clinical trial involving an experimental treatment
• People who have received immune-suppressing medications within 28 days before starting the study, or high-dose steroid medication (more than 20mg of prednisone or equivalent daily) within 7 days before starting
• People who received a live vaccine within 4 weeks before starting the study
• People who had major surgery within 4 weeks before starting the study
• People with an ongoing or recent serious infection that required intravenous (drip) antibiotics at the time of screening
• People who have tested positive for HIV, due to potential interactions between HIV medications and the study drug, and increased infection risk (confirm with trial site regarding testing procedures for those with unknown HIV status)
• People with an active human T cell leukemia virus infection, or active hepatitis B or C infection
• People with a known active cytomegalovirus (CMV) infection
• People who are pregnant, breastfeeding, or planning to breastfeed during the study or within 6 months of the last study treatment dose
• People with a condition that significantly affects how the body absorbs medications through the digestive system
• People with active, uncontrolled autoimmune conditions affecting blood cell counts
• People with other significant health conditions that could affect participation (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.